secwatch.observer — SEC 8-K summary
======================================

Issuer:     aTYR PHARMA INC (ATYR)
CIK:        0001339970
Form:       8-K
Filed at:   2023-09-11T23:59:59+00:00
Accession:  0000950170-23-047360
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

aTyr Pharma reports positive Phase 1b/2a post-hoc data for efzofitimod in sarcoidosis
--------------------------------------------------------------------------------

- Therapeutic doses (3.0 & 5.0 mg/kg) reduced steroid relapse rate to 7.7% vs 54.4% (p=0.017).
- FVC rate of change significantly improved for therapeutic vs placebo/subtherapeutic group (p=0.035).
- 52.9% of therapeutic group achieved ≥12 KSQ-L improvement (3x MCID) vs 15.0% (p=0.032).
- 64.7% of therapeutic group met composite responder endpoint vs 20.0% (p=0.008).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1339970/000095017023047360/0000950170-23-047360-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1339970/000095017023047360/life-20230910.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-047360

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer